JDRF said today it successfully persuaded Anthem to cover artificial pancreas systems, after meeting the health insurer as part of its Coverage2Control campaign. America’s 25 largest health insurers now cover Medtronic‘s (NYSE:MDT) MiniMed system, according to the organization. Get the full story at our sister site, Drug Delivery Business News.
Researchers at Boston Children’s Hospital successfully reversed Type I diabetes in a mouse model using blood stem cells, according to a study published this week in Science Translational Medicine. The researchers used cells that were pre-treated to make more of a protein, PD-L1, which is deficient in mice and people with Type I diabetes. “There’s really a reshaping […]
Voluntis said today that its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate basal insulin brands Tresiba and Basaglar. The company’s software already works with Lantus, Toujeo and Levemir. The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. […]
Bigfoot Biomedical CEO Jeffrey Brewer has spoken out about a recent data-sharing decision made by CMS, saying that he plans to lobby Medicare to reverse its latest move. Earlier this year, CMS said it would begin covering the use of particular continuous glucose monitors for people with diabetes. But since that decision, the agency has said that […]
When DarioHealth (NSDQ:DRIO) CEO Erez Raphael looks at the medical device world, he sees solutions that were designed by healthcare professionals and doctors – and this presents a stark contrast with the consumer device industry, he pointed out. “We have seen there are a lot of cases, most of the cases in the industry, where the […]
GI Dynamics (ASX:GID) said yesterday that its notified body in Europe withdrew its certification for CE Mark approval for its EndoBarrier device, meaning the company can no longer sell the obesity and diabetes treatment in the European Union. CEO Scott Schorer told MassDevice.com today during a telephone interview that Boston-based GID passed an intensive, week-long inspection of […]
A prospective study conducted by Eastern Virginia Medical School showed that patients had no diabetes-related readmissions or ER visits within 30 days of leaving the hospital when providers used the Hospital-to-Home module of Glytec‘s eGlycemic diabetes management system. Twenty-eight people with diabetes were enrolled in the study and all of them had A1C levels above 6.5% […]
Innovus Pharmaceuticals (OTC:INNV) announced today that it has inked an agreement with its current partner, Acon Laboratories, to sell Acon’s FDA-cleared glucose monitor, test strips and lancet device. The San Diego, Calif.-based company plans to sell Acon’s glucose testing kit with its GlucoGorx glucose supplement. Get the full story at our sister site, Drug Delivery Business News.
Insulet (NSDQ:PODD) up-sized the private placement that it announced yesterday, citing strong investor demand. The Billerica, Mass.-based company said today it plans to offer $350 million in convertible senior notes due in 2024, up from $300 million. Get the full story at our sister site, Drug Delivery Business News.
Bigfoot Biomedical touted data last week at this year’s Diabetes Technology Meeting showing that results from a feasibility study evaluating the company’s automated insulin delivery system closely matched data gleaned from prospective modeling. The company said it conducted extensive modeling to refine the technology’s algorithms prior to the start of its trial in 2016, Bigfoot said. […]
Insulet (NSDQ:PODD) said today that it plans to offer $300 million in convertible senior notes due in 2024 as part of a private placement. The Billerica, Mass.-based company is also slated to give initial purchasers an option to buy an additional $45 million in notes. Get the full story at our sister site, Drug Delivery Business […]